Skip to main content
Fig. 3 | Clinical Epigenetics

Fig. 3

From: Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma

Fig. 3

Outcomes of patients treated with CR-CHOP and historical control based on BCL2/MYC double expression. a PFS and OS of patients treated with CR-CHOP. b PFS and OS of patients from historical control (NCT01852435). CR-CHOP = tucidinostat (formerly known as chidamide), rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. PFS = Progression-free survival. OS = Overall survival

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us